# US 12,222,351 B2 · Immunoassay and measurement reagent for leucine-rich alpha2 glycoprotein > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,222,351 B2 - Document ID: US12222351B2 - Status: Granted - Kind: B2 - Application number: 17/282,307 - Filed: 2019-10-08 - Published: 2021-12-09 - Granted: 2025-02-11 - Earliest claimed: 2018-10-09 - Assignees: Sekisui Medical Co., Ltd.; National Institutes of Biomedical Innovation, Health and Nutrition - Applicants: Sekisui Medical Co., Ltd.; National Institutes of Biomedical Innovation, Health and Nutrition - Inventors: Shigeo Takayama; Tetsuji Naka; Satoshi Serada - Web page: https://patentgrep.com/patent/US12222351B2 ## CPC - G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor - G01N 33/545: Synthetic resin - G01N 33/543: with an insoluble carrier for immobilising immunochemicals - G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates - G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation - G01N 2800/24: Immunology or allergic disorders - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed. ## Claims ### Claim 1 An immunological measurement method for leucine-rich α2 glycoprotein (LRG) in a biologically derived sample comprising: bringing the sample into contact with at least first insoluble carrier particles carrying a first anti-LRG monoclonal antibody and second insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, wherein the first and the second insoluble carrier particles are latex particles having average particle sizes of 100 nm to 340 nm, and wherein the first and the second insoluble carrier particles are latex particles having critical coagulation concentrations of 65 mM to 270 mM. ### Claim 2 (depends on 1) The measurement method according to claim 1, wherein the average particle size of the first carrier particles carrying the first anti-LRG monoclonal antibody and the average particle size of the second insoluble carrier particles carrying the second anti-LRG monoclonal antibody are the same. ### Claim 3 (depends on 1) The measurement method according to claim 1, wherein the first insoluble carrier particles carrying the first anti-LRG monoclonal antibody and the second insoluble carrier particles carrying the second anti-LRG monoclonal antibody are contained in the same amounts in the liquid phase. ### Claim 4 (depends on 1) The measurement method according to claim 1, wherein the biologically derived sample is serum. ### Claim 5 (depends on 1) The measurement method according to claim 1, wherein the immunological measurement method is an immunoagglutination assay. ### Claim 6 (depends on 5) The measurement method according to claim 5, wherein the immunoagglutination assay is a method based on a homogeneous method. ### Claim 7 (depends on 1) The measurement method according to claim 1, wherein the step of bringing the biologically derived sample into contact with the first insoluble carrier particles carrying the first anti-LRG monoclonal antibody and the second insoluble carrier particles carrying the second anti-LRG monoclonal antibody in the liquid phase comprises the following steps: (1) bringing the sample and a first reagent containing a buffer into contact with each other in the liquid phase; and (2) adding a second reagent containing the first insoluble carrier particles carrying the first anti-LRG monoclonal antibody and the second insoluble carrier particles carrying the second anti-LRG monoclonal antibody to the liquid phase after step (1). ### Claim 8 (depends on 7) The measurement method according to claim 7, wherein the salt concentration of the liquid phase of (1) is 700 to 900 mM. ### Claim 9 (depends on 1) The measurement method according to claim 1 further comprising: optically measuring a degree of agglutination of a complex of LRG, the first insoluble carrier particles carrying the first anti-LRG monoclonal antibody and the second insoluble carrier particles carrying the second anti-LRG monoclonal antibody. ### Claim 10 (depends on 9) The measurement method according to claim 9, wherein the step of optical measuring is a step of measuring an intensity of scattered light, an absorbance or an intensity of transmitted light with an optical device. ### Claim 11 (depends on 1) The measurement method according to claim 1, wherein the latex particles have an average particle size of 150 nm to 260 nm and a critical coagulation concentration of 150 mM to 270 mM.